Charles R. Marmar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Charles R. Marmar has a total of 359 co-authors. Here are the top co-authors by number of shared publications:
- Carole Siegel
Department of Psychiatry NYU School of Medicine York New NY USA
4 shared publications - Rachel Yehuda
James J. Peters VA Medical Center, Bronx, USA
4 shared publications - Eugene Laska
Steven and Alexandra Cohen Veterans Center for the Study of Posttraumatic Stress and Traumatic Brain Injury, Department of Psychiatry, New York University School of Medicine
3 shared publications - Marti Jett
Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
3 shared publications - Owen M. Wolkowitz
Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, USA
3 shared publications - Rasha Hammamieh
Integrative Systems Biology, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
3 shared publications
Latest Publications
- Open Access
Psychiatric disorders converge on common pathways but diverge in cellular context, spatial distribution, and directionality of genetic effects
Psychiatric conditions share common genes, but mechanisms that differentiate diagnoses remain unclear. We present a multidimensional framework for functional analysis of rare copy number variants (CNVs) across 6 diagnostic categories, including schizophrenia (SCZ), autism (ASD), bipolar disorder (BD), depression (MDD), PTSD, and ADHD (N = 574,965). Using gene-set burden analysis (GSBA), we tested duplication (DUP) and deletion (DEL) burden across 2,645 functional gene sets defined by the intersections of pathways, cell types, and cortical regions. While diagnoses converge on shared pathways, mixed-effects modeling revealed divergence of pathway effects by cell type, brain region, and gene dosage. Factor analysis identified latent dimensions aligned with clinical axes. A primary factor (F1) captured reciprocal dose-dependent effects of DUP and DEL in SCZ reflecting positive and negative effects in excitatory versus inhibitory neurons and association versus sensory cortex. SCZ and ASD were both strongly aligned with F1 but with opposing directionalities. Orthogonal factors highlighted neuronal versus non-neuronal effects in mood disorders (F2) and differential spatial distributions of DEL effects in ADHD and MDD (F3). High-impact CNVs at 16p11.2 and 22q11.2 were enriched for combinations of cell-type-specific genes involved in pathways consistent with our broader findings. These results reveal molecular and cellular mechanisms that are broadly shared across psychiatric traits but differ between diagnostic categories in context and directionality.
Open AccessPsychiatric disorders converge on common pathways but diverge in cellular context, spatial distribution, and directionality of genetic effects
Psychiatric conditions share common genes, but mechanisms that differentiate diagnoses remain unclear. We present a multidimensional framework for functional analysis of rare copy number variants (CNVs) across 6 diagnostic categories, including schizophrenia (SCZ), autism (ASD), bipolar disorder (BD), depression (MDD), PTSD, and ADHD (N = 574,965). Using gene-set burden analysis (GSBA), we tested duplication (DUP) and deletion (DEL) burden across 2,645 functional gene sets defined by the intersections of pathways, cell types, and cortical regions. While diagnoses converge on shared pathways, mixed-effects modeling revealed divergence of pathway effects by cell type, brain region, and gene dosage. Factor analysis identified latent dimensions aligned with clinical axes. A primary factor (F1) captured reciprocal dose-dependent effects of DUP and DEL in SCZ reflecting positive and negative effects in excitatory versus inhibitory neurons and association versus sensory cortex. SCZ and ASD were both strongly aligned with F1 but with opposing directionalities. Orthogonal factors highlighted neuronal versus non-neuronal effects in mood disorders (F2) and differential spatial distributions of DEL effects in ADHD and MDD (F3). High-impact CNVs at 16p11.2 and 22q11.2 were enriched for combinations of cell-type-specific genes involved in pathways consistent with our broader findings. These results reveal molecular and cellular mechanisms that are broadly shared across psychiatric traits but differ between diagnostic categories in context and directionality.
- Open Access
- 7 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (5) , 1966-1975
Neuroimaging-based variability in subtyping biomarkers for psychiatric heterogeneity
Neuroimaging-based subtyping is increasingly used to explain heterogeneity in psychiatric disorders. However, the clinical utility of these subtyping efforts remains unclear, and replication has been challenging. Here we examined how the choice of neuroimaging measures influences the derivation of neuro-subtypes and the consequences for clinical delineation. On a clinically heterogeneous dataset (total n = 566) that included controls (n = 268) and cases (n = 298) of psychiatric conditions, including individuals diagnosed with post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and comorbidity of both (PTSD&TBI), we identified neuro-subtypes among the cases using either structural, resting-state, or task-based measures. The neuro-subtypes for each modality had high internal validity but did not significantly differ in their clinical and cognitive profiles. We further show that the choice of neuroimaging measures for subtyping substantially impacts the identification of neuro-subtypes, leading to low concordance across subtyping solutions. Similar variability in neuro-subtyping was found in an independent dataset (n = 1642) comprised of major depression disorder (MDD, n = 848) and controls (n = 794). Our results suggest that the highly anticipated relationships between neuro-subtypes and clinical features may be difficult to discover.
- 7 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (5) , 1966-1975
Open AccessNeuroimaging-based variability in subtyping biomarkers for psychiatric heterogeneity
Neuroimaging-based subtyping is increasingly used to explain heterogeneity in psychiatric disorders. However, the clinical utility of these subtyping efforts remains unclear, and replication has been challenging. Here we examined how the choice of neuroimaging measures influences the derivation of neuro-subtypes and the consequences for clinical delineation. On a clinically heterogeneous dataset (total n = 566) that included controls (n = 268) and cases (n = 298) of psychiatric conditions, including individuals diagnosed with post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and comorbidity of both (PTSD&TBI), we identified neuro-subtypes among the cases using either structural, resting-state, or task-based measures. The neuro-subtypes for each modality had high internal validity but did not significantly differ in their clinical and cognitive profiles. We further show that the choice of neuroimaging measures for subtyping substantially impacts the identification of neuro-subtypes, leading to low concordance across subtyping solutions. Similar variability in neuro-subtyping was found in an independent dataset (n = 1642) comprised of major depression disorder (MDD, n = 848) and controls (n = 794). Our results suggest that the highly anticipated relationships between neuro-subtypes and clinical features may be difficult to discover.
- Open Access
- 9 April 2024
- Published by Wiley in Statistical Analysis and Data Mining: An ASA Data Science Journal
- Vol. 17 (2)
A treeless absolutely random forest with closed‐form estimators of expected proximities
We introduce a simple variant of a purely random forest, called an absolute random forest (ARF) used for clustering. At every node, splits of units are determined by a randomly chosen feature and a random threshold drawn from a uniform distribution whose support, the range of the selected feature in the root node, does not change. This enables closed‐form estimators of parameters, such as pairwise proximities, to be obtained without having to grow a forest. The probabilistic structure corresponding to an ARF is called a treeless absolute random forest (TARF). With high probability, the algorithm will split units whose feature vectors are far apart and keep together units whose feature vectors are similar. Thus, the underlying structure of the data drives the growth of the tree. The expected value of pairwise proximities is obtained for three pathway functions. One, a completely common pathway function, is an indicator of whether a pair of units follow the same path from the root to the leaf node. The properties of TARF‐based proximity estimators for clustering and classification are compared to other methods in eight real‐world datasets and in simulations. Results show substantial performance and computing efficiencies of particular value for large datasets.
- 9 April 2024
- Published by Wiley in Statistical Analysis and Data Mining: An ASA Data Science Journal
- Vol. 17 (2)
Open AccessA treeless absolutely random forest with closed‐form estimators of expected proximities
We introduce a simple variant of a purely random forest, called an absolute random forest (ARF) used for clustering. At every node, splits of units are determined by a randomly chosen feature and a random threshold drawn from a uniform distribution whose support, the range of the selected feature in the root node, does not change. This enables closed‐form estimators of parameters, such as pairwise proximities, to be obtained without having to grow a forest. The probabilistic structure corresponding to an ARF is called a treeless absolute random forest (TARF). With high probability, the algorithm will split units whose feature vectors are far apart and keep together units whose feature vectors are similar. Thus, the underlying structure of the data drives the growth of the tree. The expected value of pairwise proximities is obtained for three pathway functions. One, a completely common pathway function, is an indicator of whether a pair of units follow the same path from the root to the leaf node. The properties of TARF‐based proximity estimators for clustering and classification are compared to other methods in eight real‐world datasets and in simulations. Results show substantial performance and computing efficiencies of particular value for large datasets.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S375
Abstract 2218: Analyses of metabolites over time in deployed active-duty service members
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S375
Open AccessAbstract 2218: Analyses of metabolites over time in deployed active-duty service members
- Open Access
- 21 February 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-8
Screening for PTSD and TBI in Veterans using Routine Clinical Laboratory Blood Tests
Post-traumatic stress disorder (PTSD) is a mental disorder diagnosed by clinical interviews, self-report measures and neuropsychological testing. Traumatic brain injury (TBI) can have neuropsychiatric symptoms similar to PTSD. Diagnosing PTSD and TBI is challenging and more so for providers lacking specialized training facing time pressures in primary care and other general medical settings. Diagnosis relies heavily on patient self-report and patients frequently under-report or over-report their symptoms due to stigma or seeking compensation. We aimed to create objective diagnostic screening tests utilizing Clinical Laboratory Improvement Amendments (CLIA) blood tests available in most clinical settings. CLIA blood test results were ascertained in 475 male veterans with and without PTSD and TBI following warzone exposure in Iraq or Afghanistan. Using random forest (RF) methods, four classification models were derived to predict PTSD and TBI status. CLIA features were selected utilizing a stepwise forward variable selection RF procedure. The AUC, accuracy, sensitivity, and specificity were 0.730, 0.706, 0.659, and 0.715, respectively for differentiating PTSD and healthy controls (HC), 0.704, 0.677, 0.671, and 0.681 for TBI vs. HC, 0.739, 0.742, 0.635, and 0.766 for PTSD comorbid with TBI vs HC, and 0.726, 0.723, 0.636, and 0.747 for PTSD vs. TBI. Comorbid alcohol abuse, major depressive disorder, and BMI are not confounders in these RF models. Markers of glucose metabolism and inflammation are among the most significant CLIA features in our models. Routine CLIA blood tests have the potential for discriminating PTSD and TBI cases from healthy controls and from each other. These findings hold promise for the development of accessible and low-cost biomarker tests as screening measures for PTSD and TBI in primary care and specialty settings.
- 21 February 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-8
Open AccessScreening for PTSD and TBI in Veterans using Routine Clinical Laboratory Blood Tests
Post-traumatic stress disorder (PTSD) is a mental disorder diagnosed by clinical interviews, self-report measures and neuropsychological testing. Traumatic brain injury (TBI) can have neuropsychiatric symptoms similar to PTSD. Diagnosing PTSD and TBI is challenging and more so for providers lacking specialized training facing time pressures in primary care and other general medical settings. Diagnosis relies heavily on patient self-report and patients frequently under-report or over-report their symptoms due to stigma or seeking compensation. We aimed to create objective diagnostic screening tests utilizing Clinical Laboratory Improvement Amendments (CLIA) blood tests available in most clinical settings. CLIA blood test results were ascertained in 475 male veterans with and without PTSD and TBI following warzone exposure in Iraq or Afghanistan. Using random forest (RF) methods, four classification models were derived to predict PTSD and TBI status. CLIA features were selected utilizing a stepwise forward variable selection RF procedure. The AUC, accuracy, sensitivity, and specificity were 0.730, 0.706, 0.659, and 0.715, respectively for differentiating PTSD and healthy controls (HC), 0.704, 0.677, 0.671, and 0.681 for TBI vs. HC, 0.739, 0.742, 0.635, and 0.766 for PTSD comorbid with TBI vs HC, and 0.726, 0.723, 0.636, and 0.747 for PTSD vs. TBI. Comorbid alcohol abuse, major depressive disorder, and BMI are not confounders in these RF models. Markers of glucose metabolism and inflammation are among the most significant CLIA features in our models. Routine CLIA blood tests have the potential for discriminating PTSD and TBI cases from healthy controls and from each other. These findings hold promise for the development of accessible and low-cost biomarker tests as screening measures for PTSD and TBI in primary care and specialty settings.
- Open Access
- 19 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (20) , 12504
The Genetic Basis for the Increased Prevalence of Metabolic Syndrome among Post-Traumatic Stress Disorder Patients
Post-traumatic stress disorder (PTSD) is a highly debilitating psychiatric disorder that can be triggered by exposure to extreme trauma. Even if PTSD is primarily a psychiatric condition, it is also characterized by adverse somatic comorbidities. One illness commonly co-occurring with PTSD is Metabolic syndrome (MetS), which is defined by a set of health risk/resilience factors including obesity, elevated blood pressure, lower high-density lipoprotein cholesterol, higher low-density lipoprotein cholesterol, higher triglycerides, higher fasting blood glucose and insulin resistance. Here, phenotypic association between PTSD and components of MetS are tested on a military veteran cohort comprising chronic PTSD presentation (n = 310, 47% cases, 83% male). Consistent with previous observations, we found significant phenotypic correlation between the various components of MetS and PTSD severity scores. To examine if this observed symptom correlations stem from a shared genetic background, we conducted genetic correlation analysis using summary statistics data from large-scale genetic studies. Our results show robust positive genetic correlation between PTSD and MetS (rg[SE] = 0.33 [0.056], p = 4.74E-09), and obesity-related components of MetS (rg = 0.25, SE = 0.05, p = 6.4E-08). Prioritizing genomic regions with larger local genetic correlation implicate three significant loci. Overall, these findings show significant genetic overlap between PTSD and MetS, which may in part account for the markedly increased occurrence of MetS among PTSD patients.
- 19 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (20) , 12504
Open AccessThe Genetic Basis for the Increased Prevalence of Metabolic Syndrome among Post-Traumatic Stress Disorder Patients
Post-traumatic stress disorder (PTSD) is a highly debilitating psychiatric disorder that can be triggered by exposure to extreme trauma. Even if PTSD is primarily a psychiatric condition, it is also characterized by adverse somatic comorbidities. One illness commonly co-occurring with PTSD is Metabolic syndrome (MetS), which is defined by a set of health risk/resilience factors including obesity, elevated blood pressure, lower high-density lipoprotein cholesterol, higher low-density lipoprotein cholesterol, higher triglycerides, higher fasting blood glucose and insulin resistance. Here, phenotypic association between PTSD and components of MetS are tested on a military veteran cohort comprising chronic PTSD presentation (n = 310, 47% cases, 83% male). Consistent with previous observations, we found significant phenotypic correlation between the various components of MetS and PTSD severity scores. To examine if this observed symptom correlations stem from a shared genetic background, we conducted genetic correlation analysis using summary statistics data from large-scale genetic studies. Our results show robust positive genetic correlation between PTSD and MetS (rg[SE] = 0.33 [0.056], p = 4.74E-09), and obesity-related components of MetS (rg = 0.25, SE = 0.05, p = 6.4E-08). Prioritizing genomic regions with larger local genetic correlation implicate three significant loci. Overall, these findings show significant genetic overlap between PTSD and MetS, which may in part account for the markedly increased occurrence of MetS among PTSD patients.
- 3 April 2022
- Published by Taylor & Francis in Psychiatry
- Vol. 85 (2) , 192-195
The National PTSD Brain Bank: Honoring the Vision and Contributions of Dr. Matthew Friedman
The National PTSD Brain Bank (NPBB) is a six-center consortium with an executive division at the National Center for PTSD located at the Veterans Affairs (VA) Medical Center in White River Junction...
- 3 April 2022
- Published by Taylor & Francis in Psychiatry
- Vol. 85 (2) , 192-195
The National PTSD Brain Bank: Honoring the Vision and Contributions of Dr. Matthew Friedman
The National PTSD Brain Bank (NPBB) is a six-center consortium with an executive division at the National Center for PTSD located at the Veterans Affairs (VA) Medical Center in White River Junction...
- 1 July 2020
- Published by SLACK, Inc. in Psychiatric Annals
- Vol. 50 (7) , 301-305
Guidelines for Redeploying Psychiatrists to Medicine During a Pandemic Crisis
In January 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, was identified as the causative agent for pneumonia cases in the Hubei Province of China. By March 11, 2020, coronavirus disease 2019 (COVID-19) reached pandemic levels and had spread to nearly every continent. Due to an exponential growth of cases and high rate of hospital admission, patient volume rapidly exceeded capacity. To meet demand, physicians in Asia, Europe, and the United States, regardless of their specialty, were redeployed to COVID-19 units. Redeployment of physicians involves complex decisions, such as whom to reassign, where to reassign, and how to balance needs of frontline services with those of other critical services. Guidelines for these challenging decisions are scarce. To address this critical gap in policy, we present general recommendations for redeploying psychiatrists to the medical front lines. We address levels of preparedness, complexity of the medical settings, use of house staff, medical supervision, emotional support, risk management, back-filling psychiatric services, provider diversity, and ethical, legal, and regulatory challenges. Our guidelines are general and not intended to be “one size fits all,” as we recognize that local conditions will necessitate adaptation. [ Psychiatr Ann . 2020;50(7):301–305.]
- 1 July 2020
- Published by SLACK, Inc. in Psychiatric Annals
- Vol. 50 (7) , 301-305
Guidelines for Redeploying Psychiatrists to Medicine During a Pandemic Crisis
In January 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, was identified as the causative agent for pneumonia cases in the Hubei Province of China. By March 11, 2020, coronavirus disease 2019 (COVID-19) reached pandemic levels and had spread to nearly every continent. Due to an exponential growth of cases and high rate of hospital admission, patient volume rapidly exceeded capacity. To meet demand, physicians in Asia, Europe, and the United States, regardless of their specialty, were redeployed to COVID-19 units. Redeployment of physicians involves complex decisions, such as whom to reassign, where to reassign, and how to balance needs of frontline services with those of other critical services. Guidelines for these challenging decisions are scarce. To address this critical gap in policy, we present general recommendations for redeploying psychiatrists to the medical front lines. We address levels of preparedness, complexity of the medical settings, use of house staff, medical supervision, emotional support, risk management, back-filling psychiatric services, provider diversity, and ethical, legal, and regulatory challenges. Our guidelines are general and not intended to be “one size fits all,” as we recognize that local conditions will necessitate adaptation. [ Psychiatr Ann . 2020;50(7):301–305.]
- Open Access
- 22 April 2019
- Published by Wiley in Depression and Anxiety
- Vol. 36 (7) , 607-616
Speech‐based markers for posttraumatic stress disorder in US veterans
Background The diagnosis of posttraumatic stress disorder (PTSD) is usually based on clinical interviews or self‐report measures. Both approaches are subject to under‐ and over‐reporting of symptoms. An objective test is lacking. We have developed a classifier of PTSD based on objective speech‐marker features that discriminate PTSD cases from controls. Methods Speech samples were obtained from warzone‐exposed veterans, 52 cases with PTSD and 77 controls, assessed with the Clinician‐Administered PTSD Scale. Individuals with major depressive disorder (MDD) were excluded. Audio recordings of clinical interviews were used to obtain 40,526 speech features which were input to a random forest (RF) algorithm. Results The selected RF used 18 speech features and the receiver operating characteristic curve had an area under the curve (AUC) of 0.954. At a probability of PTSD cut point of 0.423, Youden's index was 0.787, and overall correct classification rate was 89.1%. The probability of PTSD was higher for markers that indicated slower, more monotonous speech, less change in tonality, and less activation. Depression symptoms, alcohol use disorder, and TBI did not meet statistical tests to be considered confounders. Conclusions This study demonstrates that a speech‐based algorithm can objectively differentiate PTSD cases from controls. The RF classifier had a high AUC. Further validation in an independent sample and appraisal of the classifier to identify those with MDD only compared with those with PTSD comorbid with MDD is required.
- 22 April 2019
- Published by Wiley in Depression and Anxiety
- Vol. 36 (7) , 607-616
Open AccessSpeech‐based markers for posttraumatic stress disorder in US veterans
Background The diagnosis of posttraumatic stress disorder (PTSD) is usually based on clinical interviews or self‐report measures. Both approaches are subject to under‐ and over‐reporting of symptoms. An objective test is lacking. We have developed a classifier of PTSD based on objective speech‐marker features that discriminate PTSD cases from controls. Methods Speech samples were obtained from warzone‐exposed veterans, 52 cases with PTSD and 77 controls, assessed with the Clinician‐Administered PTSD Scale. Individuals with major depressive disorder (MDD) were excluded. Audio recordings of clinical interviews were used to obtain 40,526 speech features which were input to a random forest (RF) algorithm. Results The selected RF used 18 speech features and the receiver operating characteristic curve had an area under the curve (AUC) of 0.954. At a probability of PTSD cut point of 0.423, Youden's index was 0.787, and overall correct classification rate was 89.1%. The probability of PTSD was higher for markers that indicated slower, more monotonous speech, less change in tonality, and less activation. Depression symptoms, alcohol use disorder, and TBI did not meet statistical tests to be considered confounders. Conclusions This study demonstrates that a speech‐based algorithm can objectively differentiate PTSD cases from controls. The RF classifier had a high AUC. Further validation in an independent sample and appraisal of the classifier to identify those with MDD only compared with those with PTSD comorbid with MDD is required.
- Open Access
Mechanistic insights on metabolic dysfunction in PTSD: Role of glucocorticoid receptor sensitivity and energy deficit
PTSD is associated with metabolic comorbidities; however it is not clear how the neuroendocrine disturbances affect metabolism. To analyze this we employed a systems biological approach using an integrated mathematical model of metabolism, HPA axis and inflammation. We combined the metabolomics, neuroendocrine, clinical lab and cytokine data from combat-exposed veterans with and without PTSD, to characterize the differences in regulatory effects. We used the pattern of fold change in metabolites representing pathway level differences as reference for metabolic control analysis (MCA) using the model. MCA revealed parameters constituting the HPA axis, inflammation and GPCR pathway that yielded metabolic dysfunction consistent with PTSD. To support this, we performed causal analysis between regulatory components and the significantly different metabolites in our sample. Causal inference revealed that the changes in glucocorticoid receptor sensitivity were mechanistically associated with metabolic dysfunction and the effects were jointly mediated by insulin resistance, inflammation, oxidative stress and energy deficit.
Open AccessMechanistic insights on metabolic dysfunction in PTSD: Role of glucocorticoid receptor sensitivity and energy deficit
PTSD is associated with metabolic comorbidities; however it is not clear how the neuroendocrine disturbances affect metabolism. To analyze this we employed a systems biological approach using an integrated mathematical model of metabolism, HPA axis and inflammation. We combined the metabolomics, neuroendocrine, clinical lab and cytokine data from combat-exposed veterans with and without PTSD, to characterize the differences in regulatory effects. We used the pattern of fold change in metabolites representing pathway level differences as reference for metabolic control analysis (MCA) using the model. MCA revealed parameters constituting the HPA axis, inflammation and GPCR pathway that yielded metabolic dysfunction consistent with PTSD. To support this, we performed causal analysis between regulatory components and the significantly different metabolites in our sample. Causal inference revealed that the changes in glucocorticoid receptor sensitivity were mechanistically associated with metabolic dysfunction and the effects were jointly mediated by insulin resistance, inflammation, oxidative stress and energy deficit.